Roger Abrahams, MD
Pulmonary Disease · Morgantown, WVNPI 1407826787
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,407 of the $133,312 with a category attached, or 81.3%. GSK accounts for 96.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $102,963 and has fallen 95.9% since, to $4,246 in 2022. Among pulmonary disease clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $614.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$129K
- Astrazeneca UK Limited$2K
- Boehringer Ingelheim International GmbH$1K
- AstraZeneca$724
- Boehringer Ingelheim$193
- Sunovion Pharmaceuticals Inc.$54
- plus $242 from 9 others
Across 36 payments — averaging $1443.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$26K
- GSK$18K
- Sanofi US Services Inc.$7K
- Boehringer Ingelheim$2K
What the payments were for
- Consulting fees$10,7258%
- Speaking & faculty fees$108,40781%
- Travel & lodging$9,5787%
- Food & beverage$4,5773%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 151 | $129,209 |
| Astrazeneca UK Limited | 15 | $1,683 |
| Boehringer Ingelheim International GmbH | 2 | $1,207 |
| AstraZeneca | 22 | $724 |
| Boehringer Ingelheim | 9 | $193 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| Mylan Specialty L.p. | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Philips North America LLC | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Advanced Respiratory, Inc | 2 | $28 |
| CSL Behring | 1 | $16 |
| Novartis | 1 | $15 |
| Sanofi | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$59,881
- NUCALA$58,260
- ANORO$8,794
- STIOLTO$1,207
- FASENRA$300
- ANORO ELLIPTA$221
- IMFINZI$129
How this compares
$133,312 in reported general payments places this provider in the 95th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $111,601 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $24,084 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $23,753 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $15,677 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $15,509 |
| Spiriva RespimatTiotropium Bromide | 13 | $14,880 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $13,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $12,193 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,929 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 195 | $7,393 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $3,541 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,913 |
| Ventolin HfaAlbuterol Sulfate | 28 | $2,261 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,637 |
| Montelukast Sodium | 93 | $786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $129,209 | $147,547187 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $193 | $38,96544 claims |
| AstraZenecaSymbicort | $724 | $15,50937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Morgantown
- Peter KochupuraMorgantown$22K
- Sidharth BhasinMorgantown$7K
- Andrzej JaworskiMorgantown$5K
- Kyle ChapmanMorgantown$5K
- Haroon AhmedMorgantown$4K
- Mehdi FarishtaMorgantown$4K
- Sarah HadiqueMorgantown$4K
- Srinivasa PotlaMorgantown$3K
- Robert StansburyMorgantown$3K
- Joseph RussoMorgantown$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.